Company news

Correvio Pharma Corp news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Correvio Announces Brinavess Eligibility for Patent Extension

October 29, 2018

Correvio Announces Intention to Re-File Brinavess® NDA in Second Quarter 2019

October 23, 2018

Correvio to Participate In Upcoming Investor Conferences

September 20, 2018

Correvio Reports Preliminary Data Collected from >2,000 Brinavess® Treatment Episodes in EU Post-Authorization Safety Study

September 5, 2018

Correvio Highlights Completion of SteadyMed Acquisition by United Therapeutics

September 4, 2018

Correvio to Participate in Upcoming Investor Conferences

August 28, 2018

Correvio Announces EU Survey Data Demonstrating Brinavess Successfully Avoided Hospitalization in 85% of Patients

August 16, 2018

Correvio Reports Second Quarter 2018 Financial Results

August 14, 2018

Correvio Announces Brinavess® Selected as Potentially Eligible for Priority Review in China

August 14, 2018

Correvio To Report Second Quarter 2018 Financial Results On August 14, 2018

August 7, 2018

Correvio to present at the Canaccord Genuity 38th Annual Growth Conference

August 1, 2018

Correvio Announces At The Market Offering

July 10, 2018

Correvio Provides U.S. Regulatory Update for BRINAVESS

June 11, 2018

Brinavess Data Receives Top Award For Best Article Published In The Spanish Medical Journal EMERGENCIAS

June 6, 2018

Correvio Pharma Corp, Formerly Cardiome Pharma Corp, Announces Stock Ticker Symbol Change to CORV

May 17, 2018

Correvio Reports First Quarter 2018 Financial Results

May 15, 2018

Correvio Pharma Corp Completes Strategic Transaction with Cipher Pharmaceuticals

May 15, 2018

Cardiome Announces Results From Annual and Special Meeting of Shareholders and Timing For First Quarter 2018 Financial Results Conference Call

May 10, 2018

Cardiome to Present at the Bloom Burton & Co. Healthcare Investor Conference

April 26, 2018

Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®

April 17, 2018

Cardiome Announces Fifteen Xydalba(TM) and Zevtera® Abstracts at ECCMID 2018

April 12, 2018

Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds

April 6, 2018

Cardiome Highlights Partner SteadyMed's Progress Towards Trevyent NDA Resubmission

April 2, 2018

Cardiome Announces Recent Insider Purchases

March 28, 2018

Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review

March 22, 2018

Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome

March 20, 2018

Cardiome Reports Fourth Quarter and Full Year 2017 Financial Results

March 13, 2018

Cardiome to Hold Fourth Quarter and Full Year 2017 Financial Results Conference Call on March 13

March 6, 2018

Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare Conference

February 8, 2018

Cardiome Announces Expanded Label for Aggrastat® in China Including New STEMI Indication and High Dose Bolus Regimen

January 23, 2018

Cardiome to Participate in the Cantor Fitzgerald Antibiotics Summit

January 10, 2018

Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

December 12, 2017

Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

December 11, 2017

Cardiome Announces Xydalba(TM) Treatment And Patient Experience Presentations At The 2017 National Opat Conference

December 11, 2017

Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

November 20, 2017

Cardiome Reports Third Quarter 2017 Financial Results

November 14, 2017

Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

November 7, 2017

Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®

November 2, 2017

Cardiome Announces Commercial Launch of Xydalba(TM) in Three New European Geographies

October 30, 2017

Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

September 12, 2017

Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

September 5, 2017

New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BRINAVESS®

August 30, 2017

Cardiome Provides U.S. Regulatory Update For BRINAVESS

August 21, 2017

Cardiome Reports Second Quarter 2017 Financial Results

August 8, 2017

Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8

August 1, 2017

Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen

July 17, 2017

Cardiome's Partner SteadyMed Submits U.S. New Drug Application for TREVYENT® for the Treatment of Pulmonary Arterial Hypertension

July 3, 2017

Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel

June 21, 2017

Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada

June 12, 2017

Cardiome Reports Changes To Senior Management Team

May 16, 2017

← Newer news releases · Older news releases →

Decks